Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Melanoma 27Uveal Melanoma 7Neoplasms 3Skin Neoplasms 2Urologic Neoplasms 1Neoplasm Metastasis 1Eye Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × MART-1 Antigen × Clear all
NCT00019396 2024-03-04

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Skin Neoplasms, Urologic Neoplasms

NCT00295958 2012-06-14

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
26 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡